Monoclonal antibody cysteine residues (mAb cysteines)

Monoclonal antibody cysteine residues are specific amino acid sites, primarily those forming interchain disulfide bonds, that serve as the chemical foundation for the construction of antibody-drug conjugates (ADCs) (Siler et al., 2022, PubMed). In standard IgG1 antibodies, these residues are targeted via partial or full reduction to provide free thiol groups for conjugation with maleimide-functionalized linkers (Beck et al., 2017, Nature Reviews Drug Discovery). While not a traditional therapeutic target like a receptor or enzyme, these residues are critical for the site-specific delivery of cytotoxic payloads to cancer cells (Chau et al., 2019, Chemical Science). The chemical environment of these cysteines influences the stability of the resulting thioether bond, which is vital for preventing premature drug release in systemic circulation (Alley et al., 2008, Bioconjugate Chemistry). Engineering these sites allows for precise control over the drug-to-antibody ratio (DAR), a key factor in determining the efficacy and toxicity of the therapeutic agent (Sun et al., 2005, Bioconjugate Chemistry). Thus, they represent a structural pivot point in modern biopharmaceutical design rather than a biological driver of disease.

Other names

Cysteine thiolsInterchain disulfide cysteinesSulfhydryl groupsADC conjugation sites

Serves as a nucleophilic site for the covalent attachment of cytotoxic payloads via thiol-reactive linkers (e.g., maleimides) in the synthesis of antibody-drug conjugates.